Financials data is unavailable for this security.
View more
Year on year Guobang Pharma Ltd 's revenues fell -6.49% from 5.72bn to 5.35bn. This along with an increase in the cost of goods sold expense has contributed to a reduction in net income from 920.90m to 612.46m, a -33.49% decrease.
| Gross margin | 23.75% |
|---|---|
| Net profit margin | 12.10% |
| Operating margin | 13.83% |
| Return on assets | 6.66% |
|---|---|
| Return on equity | 8.94% |
| Return on investment | 8.54% |
More ▼
Cash flow in CNYView more
In 2023, Guobang Pharma Ltd increased its cash reserves by 7.59%, or 120.07m. The company earned 516.76m from its operations for a Cash Flow Margin of 9.66%. In addition the company used 361.47m on investing activities and also paid 45.94m in financing cash flows.
| Cash flow per share | -- |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 13.70 |
|---|---|
| Tangible book value per share | 13.06 |
More ▼
Balance sheet in CNYView more
| Current ratio | 2.26 |
|---|---|
| Quick ratio | 1.67 |
| Total debt/total equity | 0.2194 |
|---|---|
| Total debt/total capital | 0.1799 |
More ▼
Growth rates in CNY
Year on year, growth in earnings per share excluding extraordinary items dropped -33.49%. Additionally, five year annualized earnings per share growth ranks above the industry average relative to its peers.
| Div yield(5 year avg) | 0.83% |
|---|---|
| Div growth rate (5 year) | -- |
| Payout ratio (TTM) | 25.27% |
| EPS growth(5 years) | 23.77 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | -15.77 |
More ▼
